ÂÜÀòÂÒÂ×

Dr. Anita Das has more than 20 years of experience as a biostatistician. Anita has significant expertise in the field of anti-infective development and an in depth knowledge of clinical trial design, including determining appropriate endpoints, conduct and analysis. She previously served in senior positions in Contract Research Organizations, the pharmaceutical industry, and academia. Anita has worked on over 30 Phase 2 and 3 studies of antibiotics and antifungals in acute bacterial skin and skin infection (ABSSSI), community acquired bacterial pneumonia (CABP), complicated urinary tract infection, uncomplicated urinary tract infection, complicated intra-abdominal infection, resistant pathogens, nosocomial pneumonia (HAP/VAP), bacteremia and candidemia/invasive candidiasis leading to successful new drug applications for several antibiotics including ceftaroline, tedizolid, dalbavancin, eravacycline, lefamulin, and omadacycline. She also has extensive experience with regulatory interactions and has participated in 7 FDA Advisory Committees. She was a member of the BioMarkers Consortium of the Foundation of the National Institutes of Health which provided recommendations to the FDA on endpoints for ABSSSI, CABP and HAP/VAP studies.

Anita has a PhD in epidemiology from George Washington University and a MS in statistics from the University of Maryland, Baltimore County.